Verrica Pharmaceuticals Inc.
VRCA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VRCA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VRCA
Verrica Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing YCANTH (VP-102) for molluscum contagiosum and advancing pipeline candidates VP-315 for basal cell carcinoma and VP-102 for common warts, with Phase 3 trials underway and a history of operating losses.
Key risk: Going concern risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$97.7M
Cash Runway
5.8 moLead Asset
vp-315 (Phase 2)
Next Catalyst
Phase3_Topline · Jun 1, 2027Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials · 4 catalysts · 1 FDA decision for Verrica Pharmaceuticals Inc..
Verrica Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing YCANTH (VP-102) for molluscum contagiosum and advancing pipeline candidates VP-315 for basal cell carcinoma and VP-102 for common warts, with Phase 3 trials underway and a history of operating losses.
- Verrica's only approved product is YCANTH (VP-102) for molluscum contagiosum, with ongoing Phase 3 trials for common warts and VP-315 for basal cell carcinoma [sec_mda · as of 2026-08-06].
- As of June 30, 2026, the company had cash and equivalents of $11.5 million, total revenue of $5.9 million, and a net loss of $13.2 million [sec].
- The company has an accumulated deficit of $347.7 million as of June 30, 2026, and expects to continue incurring significant operating losses [sec_mda · as of 2026-08-06].
- Verrica is exploring non-dilutive strategic partnerships to help fund development and commercialization of VP-315 [sec_mda · as of 2026-08-06].
- The company has a going concern uncertainty and may need additional capital to fund operations [sec_mda · as of 2026-08-06].
What works
- Verrica has one FDA-approved product, YCANTH (VP-102), for molluscum contagiosum, providing a commercial revenue stream [sec_mda · as of 2026-08-06].
- The company is advancing a pipeline with Phase 3 trials for VP-102 in common warts and VP-315 in basal cell carcinoma, targeting large dermatologic markets [sec_mda · as of 2026-08-06].
- Management is actively pursuing non-dilutive strategic partnerships to support VP-315 development, potentially reducing equity dilution [sec_mda · as of 2026-08-06].
What to weigh
- Verrica has a history of operating losses and an accumulated deficit of $347.7 million as of June 30, 2026, with no near-term profitability expected [sec_mda · as of 2026-08-06].
- The company faces substantial doubt about its ability to continue as a going concern, with limited cash resources of $11.5 million as of June 30, 2026 [sec] [sec_mda · as of 2026-08-06].
- Clinical development timelines and costs are uncertain, with risks including patient enrollment, trial duration, and regulatory outcomes [sec_mda · as of 2026-08-06].
- The company's future capital requirements depend on multiple factors, including YCANTH sales, clinical trial costs, and regulatory review outcomes, which are unpredictable [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Verrica has an accumulated deficit of $347.7 million as of June 30, 2026.
“As of June 30, 2026, we had an accumulated deficit of $347.7 million.”
SEC MD&A · August 6, 2026
The company expects to continue incurring significant operating losses.
“We expect to continue to incur significant expenses and operating losses for the foreseeable future.”
SEC MD&A · August 6, 2026
Verrica is exploring non-dilutive strategic partnerships for VP-315.
“We may also pursue non-dilutive strategic partnerships to help fund the development and commercialization of VP-315.”
SEC MD&A · August 6, 2026
The company has a going concern uncertainty.
“asset amounts or the amounts and classification of liabilities that might result should we be unable to continue as a going concern.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2027-06-01 · Phase3_Topline — Phase 3 Topline: COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and S — Topline results from the COVE-2 Phase 3 trial of VP-102 for common warts are expected.
- 2027-10-01 · Phase3_Topline — Phase 3 Topline: COVE-3: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and S — Topline results from the COVE-3 Phase 3 trial of VP-102 for common warts are expected.
- 2028-05-22 · Phase3_Topline — Phase 3 Topline: COVE-4: A Phase 3, Open-Label, Long-Term Follow-Up Study to Evaluate the Safety and Efficacy of YCAN — Topline results from the COVE-4 Phase 3 trial of VP-315 for basal cell carcinoma are expected.
- 2041-02-19 · Patent_Expiry · YCANTH — Patent/Exclusivity Expiry: YCANTH — Patent or exclusivity protection for YCANTH is set to expire.
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern due to limited cash and recurring losses [sec_mda · as of 2026-08-06].
- Clinical trial uncertainty — Phase 3 trials for VP-102 and VP-315 face risks in enrollment, duration, and outcomes [sec_mda · as of 2026-08-06].
- Capital depletion risk — Cash of $11.5M as of June 30, 2026 may be insufficient to fund operations without additional financing [sec].
- Commercialization dependence — Future capital needs depend on YCANTH sales, which are uncertain [sec_mda · as of 2026-08-06].
What to watch
- Phase 3 topline data for COVE-2 (VP-102 for common warts) expected around June 1, 2027 [catalyst].
- Phase 3 topline data for COVE-3 (VP-102 for common warts) expected around October 1, 2027 [catalyst].
- Phase 3 topline data for COVE-4 (VP-315 for BCC) expected around May 22, 2028 [catalyst].
- Potential non-dilutive strategic partnerships for VP-315 development [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Verrica Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Verrica Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
5.8 months
D/E 7.36 · 0% dilution
Lead: Phase 3
2 candidates
4 upcoming, next in ~275d
6 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
38
Total value held
$23.8M
| Holder | Shares | Value |
|---|---|---|
| caligan partners lp | 923,910 | $4.9M |
| affinity asset advisors, llc | 707,338 | $3.7M |
| cannell capital llc | 685,123 | $3.6M |
| armistice capital, llc | 518,181 | $2.7M |
| vanguard capital management llc | 377,516 | $2.0M |
| boothbay fund management, llc | 280,734 | $1.5M |
| dafna capital management llc | 153,712 | $813K |
| marshall wace, llp | 140,497 | $743K |
| geode capital management, llc | 138,917 | $735K |
| stonepine capital management, llc | 99,735 | $528K |
Showing top 10 of 38 institutional holders of Verrica Pharmaceuticals Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 3.8%
- Days to cover
- 3.6
- Shares short
- 497,753
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VRCA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Verrica Pharmaceuticals Inc.?
Verrica Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing YCANTH (VP-102) for molluscum contagiosum and advancing pipeline candidates VP-315 for basal cell carcinoma and VP-102 for common warts, with Phase 3 trials underway and a history of operating losses.
What is Verrica Pharmaceuticals Inc.'s lead drug candidate?
Verrica Pharmaceuticals Inc.'s most advanced tracked candidate is vp-315 (Phase 2) for Basal Cell Carcinoma.
What is Verrica Pharmaceuticals Inc.'s next catalyst?
Verrica Pharmaceuticals Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and S" — expected June 1, 2027.
Who is the CEO of Verrica Pharmaceuticals Inc.?
Dr. Jayson M. Rieger M.B.A., Ph.D. is the chief executive officer of Verrica Pharmaceuticals Inc. (VRCA).
Where is Verrica Pharmaceuticals Inc. headquartered?
Verrica Pharmaceuticals Inc. (VRCA) is headquartered in West Chester, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.